[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100443416":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":18,"locations":31,"responsibleParty":44,"collaborators":18,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":18,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":18,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":67,"whyStopped":18,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"SPP Pharmaclon Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Drug: Interferon Gamma","EXPERIMENTAL","IFN-G administered for 2 10-day courses with a 1-week pause between the courses.",[13],"Drug: Interferon gamma human recombinant (IFN-G)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control: No intervention","NO_INTERVENTION","Any preventive method including a variety of pharmacologic therapies against COVID-19, alongside the use of antiviral and immunomodulating agents, with the exception of drugs prescribed off-label or for research purposes, and IFN-G as well.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Interferon gamma human recombinant (IFN-G)","nasal form",[9],[26],"Ingaron",[28],{"name":29,"affiliation":5,"role":30},"Anatoly I Saulin, Master","STUDY_DIRECTOR",[32],{"facility":33,"status":18,"city":34,"state":18,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":18},"City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department","Moscow","121374","Russia","RU",{"type":39,"coordinates":40},"Point",[41,42],37.61781,55.75204,{"lat":42,"lon":41},{"type":45,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100443416","study-of-the-use-of-nasal-ifn--in-patients-for-the-prevention-of-acute-respiratory-viral-infections-icluding-covid-19-100443416",true,"NCT05054114","Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19","Inclusion Criteria:\n\n* Volunteers of both sexes over 18 years of age.\n* Obtaining written informed consent.\n* Ability and consent to participate in this research.\n* Absence of symptoms of respiratory infection.\n* A negative result of a PCR study for the presence of RNA SARS-CoV-2 according to biomaterial obtained by nasopharyngeal smear.\n\nExclusion Criteria:\n\n* Any other concomitant diseases or conditions, which, in the opinion of the research doctor, may distort research results, restrict the rights of a volunteer or put him\u002Fher at greater risk.\n* Contraindications to the use of the investigated medicinal product.\n* Individual intolerance to the ingredients included in the composition of the investigational medicinal product.\n* Pregnancy or breastfeeding.\n* Doubtful result of a PCR test for the presence of RNA SARS-CoV-2 in the biomaterial obtained by nasopharyngeal smear.\n* Participation in a clinical trial using study therapy within 30 days prior to enrollment in this study.\n* Disagreement to follow in the research reliable contraceptive measures (abstinence; or a combination of 2 different methods: for example, barrier and spermicides, or barrier and intrauterine device, or barrier and hormonal, etc.) - for participants with saved reproductive potential.","ALL","18 Years",{"count":56,"type":57},630,"ACTUAL","INTERVENTIONAL",[60],"NA","It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection. In this study the primary aim is to investigate 28-day regime of nasal interferon gama use in healthy participants for COVID-19 and other respiratory infections prevention.",[63,64],"COVID-19 Respiratory Infection","Acute Respiratory Disease",[66],"COVID-19 prevention, interferon gamma, nasal drops","COMPLETED","2024-03-04",{"date":70,"type":57},"2024-08-09",{"date":72,"type":57},"2020-12-21",{"date":74,"type":57},"2021-09-02",{"name":5,"class":6},1]